It has been previously shown that the aldehyde dehydrogenase () family member has a significant association with acute myeloid leukemia (AML) patient risk group classification and that AML cells lacking expression can be readily killed via chemotherapy. In the past, however, a redundancy between the activities of subgroup members of the ALDH family has hampered the search for conclusive evidence to address the role of specific genes. Here, we describe the bioinformatics evaluation of all nineteen member genes of the family as prospective actionable targets for the development of methods aimed to improve AML treatment. We implicate in the development of recurrent AML, and we show that from the nineteen members of the family, and have the strongest association with AML patient risk group classification. Furthermore, we discover that the sum of the expression values for RNA from the genes, and , has a stronger association with AML patient risk group classification and survival than either one gene alone does. In conclusion, we identify and as prospective actionable targets for the treatment of AML in high-risk patients. Substances that inhibit both enzymatic activities constitute potentially effective pharmaceutics.